About The ASCR Network
The Adult Stem Cell Research (ASCR) Network is an Internet-based project of The Cell Therapy Foundation designed to be a well-maintained and reliable source of information for the public regarding adult stem cell research, as well as to be a community of practice and collaboration among fellow researchers. ASCR publishes the latest scientific news in the adult stem cell arena, identifies the leading researchers in the field, and locates key clinical trials; as well as connects the global community of adult stem cell researchers with one another.
BioRestorative Therapies Signs Agreement with Dexterity, Inc. to Advance Production of the Company’s Novel brtxDISC™ Stem Cell Therapy Device
Device Plays Integral Role in Delivering Stem Cells for its Proprietary Bulging/Herniated Disc Therapy
Jupiter, FL – May 20, 2013 – BioRestorative Therapies, Inc. (“BRT” or the “Company”) (OTC BB: BRTX), a life sciences company focused on developing stem cell based therapies for various personal applications, announces the signing of a consulting agreement with Dexterity, Inc. (“Dexterity”). Dexterity is a product design and bioengineering firm that will provide services to further the development and production of BRT’s proprietary therapeutic delivery device for its intervertebral disc stem cell therapy program, “brtxDISC™,” (Disc Implanted Stem Cells).
Dexterity’s work is intended to advance the design and production of the disc therapeutic delivery device, towards a final version, to be eventually used in a clinical trial as a stem cell delivery system for the treatment of bulging and herniated discs. BRT expects to have a pre-IND/IDE meeting with the FDA to discuss the clinical trial by fourth quarter of this year.
RNL BIO and Human Biostar to Offer Direct-to-Consumer Adult Stem Cell Banking in the United States
SEOUL, South Korea, May 20, 2013 /PRNewswire/ -- RNL BIO Co. Ltd., a stem cell biotechnology company dedicated to the commercialization of autologous cell therapy products for a variety of degenerative, ischemic and other indications, announces the availability of adult stem cell banking in the United States beginning on June 20, 2013. RNL BIO previously offered these services through another company, but will now provide the latest, safest technologies directly. As the sole global provider of its stem cell banking services, RNL BIO will provide clients with continuous quality assurance and constant innovation in adult stem cell technologies.
RNL BIO operates facilities in Maryland, Los Angeles and a FDA-registered stem cell banking facility in the Houston, Texas metroplex. It has opened a 15,000 square foot GMP laboratory facility in Sugar Land, Texas with extensive, state-of-the-art stem cell research and banking equipment, staffed by highly qualified scientists.
Updated: Italy reins in rogue stem-cell therapy
Posted on behalf of Alison Abbott.
A controversial decree allowing severely ill patients to continue treatment with an unproven, and possibly unsafe, stem-cell therapy may be amended, if the Italian parliament’s Chamber of Deputies has its way.
[UPDATE, 22 May 2003 — The Chamber voted in favour of the amendments on 20 May, and the amendments were accepted by the Senate on 22 May. The amended decree thus becomes law, and Stamina Foundation therapy will be available only in the context of clinical trials. Stamina head Davide Vannoni says that he will not comply with the requirement to provide the therapy for trials, according to good manufacturing practice.]
Yesterday (16 May) the Chamber’s social affairs committee unanimously passed amendments to the decree that would allow the Brescia-based Stamina Foundation, which developed the therapy, to continue administering it. However, Stamina would be required to do so within regular clinical trials, under the oversight of regulatory agencies and using cells manufactured according to Good Manufacturing Practice (GMP). A supervisory ‘observatory’ comprising experts and patient representatives would oversee clinical trial procedures.
NeoStem Announces Geographic Expansion of Intellectual Property Coverage of Cardiovascular Asset AMR-001
NEW YORK, May 16, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced the geographic expansion of intellectual property protection around its lead product candidate, AMR-001, with the notice of patent grant in Malaysia (MY-147516-A) and notice of recommendation for patent allowance in the Philippines (1-2008-501074). These patents are in the family of U.S. patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair" and protect a chemotactic stem cell product enriched for CD34+ cells that treats injury from acute myocardial infarction ("AMI").
Additionally, NeoStem has been granted a second South African patent (ZA 2011/04059) titled "Infarct Area Perfusion-Improving Compositions and Methods of Vascular Injury Repair."
* Designates sites with available clinical trials.
- * Adult Stem Cell Laboratory, Medical College of Georgia
- * Feinberg Cardiovascular Research Institute - Northwestern University, Chicago, IL
- * Indiana Center for Vascular Biology and Medicine, Laboratories - Indianapolis, IN
- * Regenerative Medicine Institute, Mexico
- * Stem Cell Center at Texas Heart Institute - Houston, TX
- Adipose Stem Cell Center, University of Pittsburgh - Pittsburgh, PA
- Adipose Tissue Plasticity - Toulouse France
- Adult Stem Cell Laboratory - Seoul, South Korea
- Adult Stem Cell Research Ctr, Seoul National University - Seoul, South Korea
- The Cardiovascular Research Institute - Washington, DC
- Center for Cardiovascular Cell Therapy - Louisville, KY
- Division of Clinical Immunology and Transfusional Medicine - Stockholm, Sweden
- Excellion Biomedical Services - Petropolis, Rio de Janeiro
- Interdisciplinary Stem Cell Institute/UM Med - Miami, FL
- Institute of Cell and Molecular Science - London, England
- Kolonin Lab - Centre for Stem Cell Research - Houston, TX
- Laboratory for Stem Cell Injury - Charleston, SC
- LIT - Laboratory of Transplantation Immunobiology - Sao Paulo, Brazil
- Minneapolis Heart Institute Foundation - Minneapolis, MN
- Molecular Cardiology Laboratory - ThoraxCenter - Rotterdam, Netherlands
- National Centre for Adult Stem Cell Research at Griffith University - Nathan Queensland, Australia
- Naviaux Lab - The Mitochondrial and Metabolic Disease Center - San Diego, CA
- Oklahoma Center for Adult Stem Cell Research (OCASCR) - Oklahoma City, OK
- Penn Lab - Cleveland Clinic - Cleveland, OH
- Prantl Laboratory - Center for Adult Stem Cell Research - Regensburg, Germany
- Research & Development Unit - National Heart Centre, Singapore
- RhinoCyte™, Inc. - Louisville, KY
- Scandurro Research Laboratory - New Orleans, LA
- Simari Lab - Mayo Clinic - Rochester, MN
- Skeletal Tissue Engineering Group - Amsterdam
- Skeletal Research Center, Case Western Reserve University - Cleveland, OH
- Stem Cell Biology Laboratory, Pennington Biomedical Research Center - Baton Rouge, LA
- Stem Cell Biology and Cell Therapy Laboratory - Philadelphia, PA
- Stem Cell Research Center - Pittsburgh, PA
- Stem Cell Research Center - Taipei, Taiwan
- Yoder Laboratory - Indianapolis, IN
- Wake Forest Institute of Regenerative Medicine - Winston-Salem, NC